Warning: The NCBI web site requires JavaScript to function. more...
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Bivi N, Romanello M, Harrison R, Clarke I, Hoyle DC, Moro L, Ortolani F, Bonetti A, Quadrifoglio F, Tell G, Delneri D.
Genome Biol. 2009;10(9):R93. Epub 2009 Sep 10.
Related citations
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.
J Bone Miner Res. 1998 Apr;13(4):581-9.
Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
Eur J Pharmacol. 2007 Sep 10;570(1-3):27-37. Epub 2007 Jun 16.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Nishiguchi T, Akiyoshi T, Anami S, Nakabayashi T, Matsuyama K, Matzno S.
J Pharm Pharmacol. 2009 Jun;61(6):781-8.
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC, Rogers MJ.
J Bone Miner Res. 2003 Feb;18(2):204-12.
Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG, Rogers MJ.
Bone. 1999 Jul;25(1):97-106. Review.
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R.
J Biol Chem. 2001 Sep 7;276(36):33930-7. Epub 2001 Jul 2.
Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
Merrell MA, Wakchoure S, Ilvesaro JM, Zinn K, Gehrs B, Lehenkari PP, Harris KW, Selander KS.
Eur J Pharmacol. 2007 Mar 15;559(1):21-31. Epub 2006 Dec 9.
The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E, Löwik C, van der Pluijm G, Papapoulos S.
J Bone Miner Res. 1999 May;14(5):722-9.
Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, Komiya S.
Anticancer Res. 2008 Jul-Aug;28(4B):2147-54.
The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
Bone. 2011 Jul;49(1):20-33. Epub 2011 Apr 9. Review.
Bisphosphonates: mode of action and pharmacology.
Russell RG.
Pediatrics. 2007 Mar;119 Suppl 2:S150-62. Review.
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
Differential effects of bisphosphonates on breast cancer cell lines.
Verdijk R, Franke HR, Wolbers F, Vermes I.
Cancer Lett. 2007 Feb 8;246(1-2):308-12. Epub 2006 Apr 18.
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.
Osteoblast proliferation and maturation by bisphosphonates.
Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS.
Biomaterials. 2004 Aug;25(18):4105-15.
Mechanisms of cell cycle control revealed by a systematic and quantitative overexpression screen in S. cerevisiae.
Niu W, Li Z, Zhan W, Iyer VR, Marcotte EM.
PLoS Genet. 2008 Jul 11;4(7):e1000120.
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD, Delmas PD.
Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. Review.
An update on bisphosphonates.
Cohen SB.
Curr Rheumatol Rep. 2004 Feb;6(1):59-65. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on